was treated unevenfully with a drug-eluting balloon angioplasty. Three severely stenosed external carotid arteries (ECAs) occluded at CAS; ECA patency rate was 97.0% post CAS and at 30 days, and 97% at 12 months. At 12 months, in-stent velocities were normal (PSV 0.81±0.3; EDV 0.21±0.3m/s).
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Cardiac strength deconditioning after the 60-days head-down bed-rest assessed by heart kinetic energy wearable monitoring Head-down tilt bed-rest (HDBR) simulates cardiac deconditioning that occur during long duration space flight. The effects of 60-days HDBR were assessed by a novel non-invasive wearable heart kinetic (HK) cardiac monitoring method based on calibrated combination of multi-dimensional Ballistocardiography (BCG) and Seismocardiography (SCG). Results were compared to phase-contrast (PC) MRIderived stroke volume (SV). Our hypothesis was that lower stroke volume (SV) would be associated with lower HK as a marker of cardiac contractility. HK was measured during the ESA-RSL-BR study in a controlled breathing (CB) protocol (7.5 breath per minute) performed before (PRE) and after 58-days (HDT58) of BR on24 healthy males (mean age 28±6). Aortic PC-MRI was performed and blood velocities were integrated over the aortic lumen area to compute SV. During CB, we recorded ECG, ICG, respiration, SCG, and overall linear (lin) and angular (rot) accelerations in 6-degrees of freedom with a miniature accelerometer placed in the lumbar region. Newtonian equations of kinematics were used to compute total heart kinetic energy (HKtot), the sum of HKrot and HKlin, the energy transferred to the body by each cardiac contraction and a marker of cardiac contractility.
Comparison between HDT58 and PRE showed a significant (p<.05, paired t-test) decrease in SV (22%) and a decrease in HKtot (27%) and HKrot (30%) but not in HKlin. 
Introduction:
Statins reduce low-density lipoprotein cholesterol (LDL-C) and thereby cardiovascular (CV) risk. However, in many countries, disease awareness, access to treatment and patient adherence are low, and treatment duration is often less than 3 months. Patient-focussed mobile health (mHealth) technology using smart phone apps has the potential to provide support to large numbers of patients at a cost that is sustainable over a long time. However, limited data exist on the impact of these tools. This is the first study to assess the impact of a mHealth tool on statin treatment duration and is an important step towards generation of evidence for patient focused mHealth. Purpose: A randomised, two-arm, open-label exploratory study to evaluate if a smart phone-based patient support tool prolongs statin treatment duration in patients at high CV risk. Methods: Patients newly prescribed a statin in China were randomised (1:1) to an Active group, which received the smart phone-based patient support tool or to a Control group, which received only a control app. Both groups completed a questionnaire specifically developed to evaluate adherence via their smart phone. The primary outcome was duration of statin treatment (time from randomisation to last patient-reported visit to a doctor for prescription renewal plus the number of days of the last prescription). Secondary outcomes were percentage of fully adherent patients, treatment adherence and percent change in LDL-C at Week 24. Results: At baseline, mean age was 55 years, 63% were men, BMI was 26 kg/m 2 , 30% were smokers and LDL-C was 139 mg/dL, with no difference between groups. Primary outcome data were available for 431 patients in the Active group and 423 in the Control group. There was a trend, though not statistically significant, toward a longer mean duration of treatment in the Active group (105 days) vs the Control group (99 days) (p=0.097). For secondary outcomes, there were more patients who rated themselves as fully adherent in the Control group (9.9%, n=42) than in the Active group (4.4%, n=19) (p=0.002). Treatment adherence in terms of patient reported number of pills taken divided by the total number of patient reported days in the study varied and depended on response rate. There was no statistically significant difference in reduction of LDL-C between the two groups at Week 24. None of the reported 43 adverse events were considered to depend on the app or on rosuvastatin.
Conclusions: This innovative study shows a trend towards prolongation of duration of statin treatment with a smart phone-based patient support tool, although not statistically significant. mHealth will have a future to educate and motivate patients to be more adherent, in China and other countries. Further studies to evaluate similar support tools and technology are needed. Acknowledgement/Funding: This study was funded by AstraZeneca. Medical writing support was provided by Kerren Davenport, Prime, funded by AstraZeneca.
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